Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
| ▸ | POLA1 | P09884 | 1/20 | 0.34 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 2/20 | 0.34 |
| ▸ | EGLN1 | Q9GZT9 | 2/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6669028 | 0.94 | MAPK1 (0.39) | MAPK1POLA1KCNH2GAAEGLN1 | |
| SCHEMBL6667328 | 0.90 | MAPK1 (0.37) | MAPK1POLA1KCNH2GAAEGLN1 | |
| SCHEMBL6669484 | 0.88 | MAPK1 (0.36) | MAPK1POLA1GAAEGLN1KMT2A | |
| SCHEMBL6694192 | 0.87 | CACNA1C (0.33) | MAPK1POLA1KCNH2EGLN1KMT2A | |
| SCHEMBL6669311 | 0.86 | KCNH2 (0.48) | POLA1KCNH2ALDH1A1 | |
| SCHEMBL6667340 | 0.85 | PTGER4 (0.34) | MAPK1EGLN1KMT2A | |
| SCHEMBL6669978 | 0.84 | MAPK1 (0.38) | MAPK1KCNH2GAAEGLN1SMN1; SMN2 | |
| SCHEMBL6668056 | 0.83 | MAPK1 (0.39) | MAPK1POLA1KCNH2GAASMN1; SMN2 | |
| SCHEMBL6672693 | 0.83 | MAPK1 (0.38) | MAPK1POLA1KCNH2GAASMN1; SMN2 | |
| SCHEMBL6670944 | 0.82 | NPC1 (0.33) | MAPK1POLA1KCNH2GAAEGLN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040067947-A1 | Method of preventing or treating atherosclerosis or restenosis | WATHEN MICHAEL W | 2004-04-08 | — | — | US | claimed |
| WO-2004019940-A1 | METHOD OF PREVENTING OR TREATING ATHEROSCLEROSIS OR RESTENOSIS | PHARMACIA & UPJOHN COMPANY (US) | 2004-03-11 | — | — | WO | claimed |
| EP-1265872-A1 | 4-HYDROXYCINNOLINE-3-CARBOXYAMIDES AS ANTIVIRAL AGENTS | PHARMACIA & UPJOHN COMPANY (US) | 2002-12-18 | — | — | EP | claimed |
| US-6458788-B1 | VIRICIDES; HERPES VIRUS | PHARMACIA & UPJOHN COMPANY | 2002-10-01 | — | — | US | claimed |
| US-20020042397-A1 | 4-hydroxycinnoline-3-carboxyamides as antiviral agents | PHARMACIA & UPJOHN COMPANY | 2002-04-11 | — | — | US | claimed |
| WO-2001081318-A1 | 4-HYDROXYCINNOLINE-3-CARBOXYAMIDES AS ANTIVIRAL AGENTS | PHARMACIA & UPJOHN COMPANY (US) | 2001-11-01 | — | — | WO | claimed |
| US-20040067947-A1 | Method of preventing or treating atherosclerosis or restenosis | WATHEN MICHAEL W | 2004-04-08 | — | — | US | disclosed |
| WO-2004019940-A1 | METHOD OF PREVENTING OR TREATING ATHEROSCLEROSIS OR RESTENOSIS | PHARMACIA & UPJOHN COMPANY (US) | 2004-03-11 | — | — | WO | disclosed |
| EP-1265872-A1 | 4-HYDROXYCINNOLINE-3-CARBOXYAMIDES AS ANTIVIRAL AGENTS | PHARMACIA & UPJOHN COMPANY (US) | 2002-12-18 | — | — | EP | disclosed |
| US-6458788-B1 | VIRICIDES; HERPES VIRUS | PHARMACIA & UPJOHN COMPANY | 2002-10-01 | — | — | US | disclosed |
| US-20020042397-A1 | 4-hydroxycinnoline-3-carboxyamides as antiviral agents | PHARMACIA & UPJOHN COMPANY | 2002-04-11 | — | — | US | disclosed |
| WO-2001081318-A1 | 4-HYDROXYCINNOLINE-3-CARBOXYAMIDES AS ANTIVIRAL AGENTS | PHARMACIA & UPJOHN COMPANY (US) | 2001-11-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020042397-A1 | 4-hydroxycinnoline-3-carboxyamides as antiviral agents | HAVCR2, ZC3HAV1, HCFC1 | MAPK1 4363/4885POLA1 2405/4885KCNH2 1186/4885 |
| US-20040067947-A1 | Method of preventing or treating atherosclerosis or restenosis | LDLR, MSR1, NR1H2 | MAPK1 737/4885POLA1 2850/4885KCNH2 4046/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.